{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:10:03Z","timestamp":1746850203585,"version":"3.40.5"},"reference-count":79,"publisher":"Japan Endocrine Society","issue":"5","funder":[{"DOI":"10.13039\/100021128","name":"Hyogo Science and Technology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology","award":["22K08654"],"award-info":[{"award-number":["22K08654"]}]},{"name":"Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology","award":["19K09003"],"award-info":[{"award-number":["19K09003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0309","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T22:12:36Z","timestamp":1741299156000},"page":"463-473","source":"Crossref","is-referenced-by-count":0,"title":["Management of Cushing\u2019s disease in the initial phase~From detection to surgery~"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"first","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe 650-0017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50: 137\u2013195."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Mason HL, Meyers CS, Kendall EC (1936) Chemical studies of the suprarenal cortex: II. The identification of a substance which possesses the qualitative action of cortin; its conversion into a diketone closely related to androstenedione. J Biol Chem 116: 267\u2013276.","DOI":"10.1016\/S0021-9258(18)74681-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Li CH, Geschwind II, Levy AL, Harris JI, Dixon JS, et al. (1954) Isolation and properties of alpha-corticotrophin from sheep pituitary glands. Nature 173: 251\u2013253.","DOI":"10.1038\/173251b0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, et al. (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43: 1003\u20131037.","DOI":"10.1210\/endrev\/bnac010"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386: 913\u2013927.","DOI":"10.1016\/S0140-6736(14)61375-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19: 581\u2013599.","DOI":"10.1038\/s41574-023-00868-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, et al. (2019) Overall and disease-specific mortality in patients with cushing disease: a swedish nationwide study. J Clin Endocrinol Metab 104: 2375\u20132384.","DOI":"10.1210\/jc.2018-02524"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382: 937\u2013950.","DOI":"10.1056\/NEJMra1810772"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Webb SM, Santos A, Resmini E, Mart\u00ednez-Mombl\u00e1n MA, Martel L, et al. (2018) Quality of life in Cushing\u2019s disease: a long term issue? Ann Endocrinol (Paris) 79: 132\u2013137.","DOI":"10.1016\/j.ando.2018.03.007"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, et al. (1992) Effects of an Rb mutation in the mouse. Nature 359: 295\u2013300.","DOI":"10.1038\/359295a0"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721\u2013732.","DOI":"10.1016\/S0092-8674(00)81238-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, et al. (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103: 15558\u201315563.","DOI":"10.1073\/pnas.0603877103"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, et al. (2010) Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol 24: 1835\u20131845.","DOI":"10.1210\/me.2010-0091"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, et al. (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183: 385\u2013394.","DOI":"10.1677\/joe.1.05616"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, et al. (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121: 4712\u20134721.","DOI":"10.1172\/JCI60417"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Araki T, Liu X, Kameda H, Tone Y, Fukuoka H, et al. (2017) EGFR induces E2F1-mediated corticotroph tumorigenesis. J Endocr Soc 1: 127\u2013143.","DOI":"10.1210\/js.2016-1053"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, et al. (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47: 31\u201338.","DOI":"10.1038\/ng.3166"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, et al. (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25: 306\u2013317.","DOI":"10.1038\/cr.2015.20"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Weigand I, Knobloch L, Flitsch J, Saeger W, Monoranu CM, et al. (2019) Impact of USP8 gene mutations on protein deregulation in Cushing disease. J Clin Endocrinol Metab 104: 2535\u20132546.","DOI":"10.1210\/jc.2018-02564"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20 Shichi H, Fukuoka H, Kanzawa M, Yamamoto M, Yamamoto N, et al. (2022) Responsiveness to DDAVP in Cushing\u2019s disease is associated with USP8 mutations through enhancing AVPR1B promoter activity. Pituitary 25: 496\u2013507.","DOI":"10.1007\/s11102-022-01220-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Perez-Rivas LG, Theodoropoulou M, Ferra\u00f9 F, Nusser C, Kawaguchi K, et al. (2015) The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing\u2019s disease. J Clin Endocrinol Metab 100: E997\u2013E1004.","DOI":"10.1210\/jc.2015-1453"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, et al. (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol 174: 213\u2013226.","DOI":"10.1530\/EJE-15-0689"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Losa M, Mortini P, Pagnano A, Detomas M, Cassarino MF, et al. (2019) Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas. Endocrine 63: 240\u2013246.","DOI":"10.1007\/s12020-018-1776-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Sesta A, Cassarino MF, Terreni M, Ambrogio AG, Libera L, et al. (2020) Ubiquitin-specific protease 8 mutant corticotrope adenomas present unique secretory and molecular features and shed light on the role of ubiquitylation on ACTH processing. Neuroendocrinology 110: 119\u2013129.","DOI":"10.1159\/000500688"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Chen J, Jian X, Deng S, Ma Z, Shou X, et al. (2018) Identification of recurrent USP48 and BRAF mutations in Cushing\u2019s disease. Nat Commun 9: 3171.","DOI":"10.1038\/s41467-018-05275-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, et al. (2019) Driver mutations in USP8 wild-type Cushing\u2019s disease. Neuro Oncol 21: 1273\u20131283.","DOI":"10.1093\/neuonc\/noz109"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Nadhamuni VS, Korbonits M (2020) Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms. Endocr Rev 41: 821\u2013846.","DOI":"10.1210\/endrev\/bnaa006"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Abraham AP, Pai R, Beno DL, Chacko G, Asha HS, et al. (2022) USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing\u2019s disease. Endocrine 75: 549\u2013559.","DOI":"10.1007\/s12020-021-02903-x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Miao H, Liu Y, Lu L, Gong F, Wang L, et al. (2021) Effect of 3 NR3C1 mutations in the pathogenesis of pituitary ACTH adenoma. Endocrinology 162: bqab167.","DOI":"10.1210\/endocr\/bqab167"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Chen Z, Jia Q, Zhao Z, Zhang Q, Chen Y, et al. (2022) Transcription factor ASCL1 acts as a novel potential therapeutic target for the treatment of the Cushing\u2019s disease. J Clin Endocrinol Metab 107: 2296\u20132306.","DOI":"10.1210\/clinem\/dgac280"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Uzilov AV, Taik P, Cheesman KC, Javanmard P, Ying K, et al. (2021) USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors. J Clin Endocrinol Metab 106: 826\u2013842.","DOI":"10.1210\/clinem\/dgaa853"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Perez-Rivas LG, Simon J, Albani A, Tang S, Roeber S, et al. (2022) TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun 10: 139.","DOI":"10.1186\/s40478-022-01437-1"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Casar-Borota O, Boldt HB, Engstr\u00f6m BE, Andersen MS, Baussart B, et al. (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 106: 1183\u20131194.","DOI":"10.1210\/clinem\/dgaa749"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Asuzu DT, Alvarez R, Fletcher PA, Mandal D, Johnson K, et al. (2022) Pituitary adenomas evade apoptosis <i>via<\/i> noxa deregulation in Cushing\u2019s disease. Cell Rep 40: 111223.","DOI":"10.1016\/j.celrep.2022.111223"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Lindholm J, Juul S, J\u00f8rgensen JO, Astrup J, Bjerre P, et al. (2001) Incidence and late prognosis of cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab 86: 117\u2013123.","DOI":"10.1210\/jcem.86.1.7093"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Arnard\u00f3ttir S, Sigurjonsd\u00f3ttir HA (2011) The incidence and prevalence of Cushing\u2019s disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009. Clin Endocrinol (Oxf) 74: 792\u2013793.","DOI":"10.1111\/j.1365-2265.2010.03961.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O (2019) The incidence of endogenous Cushing\u2019s syndrome in the modern era. Clin Endocrinol (Oxf) 91: 263\u2013270.","DOI":"10.1111\/cen.14014"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, et al. (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173: 655\u2013664.","DOI":"10.1530\/EJE-15-0189"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Takayanagi R, Miura K, Nakagawa H, Nawata H (2000) Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother 54 Suppl 1: 164s\u2013168s.","DOI":"10.1016\/S0753-3322(00)80036-0"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Alexandraki KI, Kaltsas GA, Isidori AM, Akker SA, Drake WM, et al. (2009) The prevalence and characteristic features of cyclicity and variability in Cushing\u2019s disease. Eur J Endocrinol 160: 1011\u20131018.","DOI":"10.1530\/EJE-09-0046"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Nowak E, Vogel F, Albani A, Braun L, Rubinstein G, et al. (2023) Diagnostic challenges in cyclic Cushing\u2019s syndrome: a systematic review. Lancet Diabetes Endocrinol 11: 593\u2013606.","DOI":"10.1016\/S2213-8587(23)00150-X"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Steffensen C, Pereira AM, Dekkers OM, J\u00f8rgensen JO (2016) Diagnosis of Endocrine Disease: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol 175: R247\u2013R253.","DOI":"10.1530\/EJE-16-0434"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Anderson GH Jr, Blakeman N, Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12: 609\u2013615.","DOI":"10.1097\/00004872-199405000-00015"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27: 193\u2013202.","DOI":"10.1291\/hypres.27.193"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, et al. (2002) Overnight dexamethasone suppression test: a reliable screen for Cushing\u2019s syndrome in the obese. Obes Res 10: 1217\u20131221.","DOI":"10.1038\/oby.2002.166"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Tsujimoto Y, Shichi H, Fukuoka H, Yamamoto M, Sato I, et al. (2021) Tumor shrinkage by metyrapone in Cushing disease exhibiting glucocorticoid-induced positive feedback. J Endocr Soc 5: bvab055.","DOI":"10.1210\/jendso\/bvab055"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, et al. (2020) Time to diagnosis in Cushing\u2019s syndrome: a meta\u2013analysis based on 5367 patients. J Clin Endocrinol Metab 105: dgz136.","DOI":"10.1210\/clinem\/dgz136"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, et al. (2015) From first symptoms to final diagnosis of Cushing\u2019s disease: experiences of 176 patients. Eur J Endocrinol 172: 285\u2013289.","DOI":"10.1530\/EJE-14-0766"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526\u20131540.","DOI":"10.1210\/jc.2008-0125"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Braun LT, Vogel F, Zopp S, Seiter TM, Rubinstein G, et al. (2022) Whom should we screen for Cushing syndrome? The endocrine society practice guideline recommendations 2008 revisited. J Clin Endocrinol Metab 107: e3723\u2013e3730.","DOI":"10.1210\/clinem\/dgac379"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51 Motomura Y, Urai S, Bando H, Yamamoto M, Suzuki M, et al. (2024) Diagnostic dilemma in Cushing\u2019s syndrome: discrepancy between patient-reported and physician-assessed manifestations. Endocrine 86: 417\u2013427.","DOI":"10.1007\/s12020-024-03935-9"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Stratakis CA (2016) Skin manifestations of Cushing\u2019s syndrome. Rev Endocr Metab Disord 17: 283\u2013286.","DOI":"10.1007\/s11154-016-9399-3"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Erden F, Borlu M, Simsek Y, Kelestemur HF (2019) Differences in skin lesions of endogenous and exogenous Cushing\u2019s patients. Postepy Dermatol Alergol 36: 272\u2013275.","DOI":"10.5114\/ada.2018.74639"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, et al. (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9: 847\u2013875.","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, et al. (2013) Evaluation of the diagnostic criteria for Cushing\u2019s disease in Japan. Endocr J 60: 127\u2013135.","DOI":"10.1507\/endocrj.EJ12-0299"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Findling JW, Raff H (2017) Diagnosis of endocrine disease: differentiation of pathologic\/neoplastic hypercortisolism (Cushing\u2019s syndrome) from physiologic\/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing\u2019s syndrome). Eur J Endocrinol 176: R205\u2013R216.","DOI":"10.1530\/EJE-16-0946"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Scaroni C, Albiger NM, Palmieri S, Iacuaniello D, Graziadio C, et al. (2020) Approach to patients with pseudo-Cushing\u2019s states. Endocr Connect 9: R1\u2013R13.","DOI":"10.1530\/EC-19-0435"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Brien TG (1981) Human corticosteroid binding globulin. Clin Endocrinol (Oxf) 14: 193\u2013212.","DOI":"10.1111\/j.1365-2265.1981.tb00616.x"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Bando H, Kanie K, Yamamoto M, Fukuoka H (2023) High cortisol concentration without cushingoid appearance. Am J Med 136: e43\u2013e44.","DOI":"10.1016\/j.amjmed.2022.10.009"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Hwang S, Tatsi C, Kuehn HS, Niemela JE, Stoddard J, et al. (2022) Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21. J Allergy Clin Immunol 149: 302\u2013314.","DOI":"10.1016\/j.jaci.2021.05.031"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, et al. (2009) Hypercoagulable state in Cushing\u2019s syndrome: a systematic review. J Clin Endocrinol Metab 94: 2743\u20132750.","DOI":"10.1210\/jc.2009-0290"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Fukuoka H, Takeuchi T, Matsumoto R, Bando H, Suda K, et al. (2014) D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing\u2019s syndrome. Endocr J 61: 1003\u20131010.","DOI":"10.1507\/endocrj.EJ14-0102"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Putignano P, Kaltsas GA, Korbonits M, Jenkins PJ, Monson JP, et al. (2000) Alterations in serum protein levels in patients with Cushing\u2019s syndrome before and after successful treatment. J Clin Endocrinol Metab 85: 3309\u20133312.","DOI":"10.1210\/jcem.85.9.6833"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Ceccato F, Barbot M, Mondin A, Boscaro M, Fleseriu M, et al. (2023) Dynamic testing for differential diagnosis of ACTH-dependent Cushing syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 108: e178\u2013e188.","DOI":"10.1210\/clinem\/dgac686"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Suda T, Kageyama K, Nigawara T, Sakihara S (2009) Evaluation of diagnostic tests for ACTH-dependent Cushing\u2019s syndrome. Endocr J 56: 469\u2013476.","DOI":"10.1507\/endocrj.K08E-353"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, et al. (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4: 611\u2013629.","DOI":"10.1016\/S2213-8587(16)00086-3"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, et al. (2015) Treatment of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100: 2807\u20132831.","DOI":"10.1210\/jc.2015-1818"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Lugat A, Lasolle H, Fran\u00e7ois M, Benhenda N, Bricaire L, et al. (2023) Pneumocystis pneumonia in patients with Cushing\u2019s syndrome: a French multicenter retrospective study. Ann Endocrinol (Paris) 84: 37\u201344.","DOI":"10.1016\/j.ando.2022.09.020"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Varlamov EV, Langlois F, Vila G, Fleseriu M (2021) Management of endocrine disease: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing\u2019s syndrome: a practical approach. Eur J Endocrinol 184: R207\u2013R224.","DOI":"10.1530\/EJE-20-1309"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, et al. (2011) Incidence of venous thromboembolism in patients with Cushing\u2019s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96: 3525\u20133532.","DOI":"10.1210\/jc.2011-1661"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Beuschlein F, Else T, Bancos I, Hahner S, Hamidi O, et al. (2024) European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab 109: 1657\u20131683.","DOI":"10.1210\/clinem\/dgae250"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, et al. (2018) Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 178: 399\u2013409.","DOI":"10.1530\/EJE-17-0997"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, et al. (2015) Mechanisms in endocrinology: Cushing\u2019s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173: R1\u2013R14.","DOI":"10.1530\/EJE-14-1101"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Papakokkinou E, Ragnarsson O (2023) Functional brain alterations in Cushing\u2019s syndrome. Front Endocrinol (Lausanne) 14: 1163482.","DOI":"10.3389\/fendo.2023.1163482"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Pupier E, Santos A, Etchamendy N, Lavielle A, Ferriere A, et al. (2022) Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing\u2019s disease in remission. Front Endocrinol (Lausanne) 13: 934347.","DOI":"10.3389\/fendo.2022.934347"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 106: 2114\u20132123.","DOI":"10.1210\/clinem\/dgab122"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, et al. (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182: 207\u2013217.","DOI":"10.1530\/EJE-19-0695"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Yoshida K, Fukuoka H, Odake Y, Nakajima S, Tachibana M, et al. (2017) Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with Cushing\u2019s syndromes treatment: case presentations. Front Endocrinol (Lausanne) 8: 375.","DOI":"10.3389\/fendo.2017.00375"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79 Fleseriu M, Biller BMK (2022) Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 25: 795\u2013809.","DOI":"10.1007\/s11102-022-01268-2"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/5\/72_EJ24-0309\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:32:29Z","timestamp":1746847949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/5\/72_EJ24-0309\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0309","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0309"}}